Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06634589
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-08
Brief Title:
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1b2 Open-Label Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to measure the safety preliminary antitumor activity pharmacokinetics and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory RR B-cell malignancies This study is structured as a master protocol with separate substudies This study will initially include two substudies and more substudies may be added as they become available
Detailed Description:
This new study will check how safe and helpful a potential anticancer drug called BGB-16673 is in participants with RR B-cell malignancies when it is given in combination with other medicines - sonrotoclax in substudy 1 and with zanubrutinib in substudy 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None